• Markets
• News
• Learn

Ingevity (NGVT) posts mixed FY 2025 finish as earnings swing

Ingevity (NGVT) just closed FY 2025 with Q4 revenue of US$255.1 million and basic EPS of a US$2.21 loss, a sharp contrast to Q4 FY 2024 when revenue was US$298.8 million and EPS was US$0.46. Over recent quarters the company has seen revenue move from US$340.1 million in Q1 2024 to US$284 million in Q1 2025, and from US$333.8 million in Q3 2024 to US$333.1 million in Q3 2025. Quarterly EPS has ranged from a US$1.54 loss in Q1 2024 to US$1.31 in Q3 2024 and US$1.12 in Q3 2025, before slipping back into the red in the latest quarter. This sets up a results season in which investors are likely to focus squarely on how quickly margins can stabilize from here.

With the headline numbers on the table, the next step is to see how this earnings print lines up against the main stories circulating around Ingevity, highlighting where the fresh data backs those narratives and where it pushes back.

See what the community is saying about Ingevity

Trailing losses still weigh on the story

• On a trailing 12 month basis, Ingevity generated US$1.17b of revenue but reported a net loss of US$150.3 million and basic EPS of US$4.15 loss, so the company is still unprofitable over the full year even though some individual quarters were positive.
• Analysts' consensus view points to a business in transition, with portfolio changes and cost work expected to support more resilient margins over time, yet the current loss profile shows the company is not there yet.
  • Consensus commentary highlights efforts like divesting lower margin operations and focusing on higher value specialty chemicals as potential support for future margin stability, but the latest trailing numbers still reflect weak earnings quality.
  • The same consensus view references investments in areas such as EV related materials and process purification as future growth drivers, which sit against a starting point of modest revenue growth of about 3.5% per year and sustained losses over the past five years.

Revenue growth modest versus expectations

• Revenue over the last year implies about 3.5% annual growth, compared with a 10.4% growth rate forecast for the wider US market, so Ingevity is growing but at a slower pace than that broader benchmark.
• Looking at the bullish angle, forecasts for earnings to turn positive and grow very quickly rest on this modest top line, which creates a clear tension.
  • Supporters of the bullish view point to analysts expecting profit margins to move from a current level of roughly 16.3% loss to a positive 28.4% in about three years, even though recent quarterly net income excluding extra items ranged from a loss of US$78.8 million in Q4 2025 to a profit of US$47.5 million in Q3 2024.
  • Those same forecasts see earnings reaching US$412.8 million and EPS of US$5.9 by around 2028, which would be a very large swing from the current trailing loss of US$150.3 million and basic EPS of US$4.15 loss, so anyone relying on the bullish case needs to be comfortable with that jump.

Valuation and debt pull in opposite directions

• The shares trade on a P/S of 2.2x compared with 1.2x for the US Chemicals industry and 1.3x for peers, while a DCF fair value of about US$119.88 per share sits well above the current share price of US$70.52, so simple multiples and the DCF signal send different messages.
• Bears focus on the combination of high leverage and these richer P/S multiples, arguing that this mix could be a risk if the forecast turnaround does not play out as modeled.
  • The company has been flagged as having a high level of debt at the same time as trailing earnings remain negative, which leaves less room for error if revenue growth stays around 3.5% a year rather than moving higher.
  • Critics also point to the five year record of losses worsening at about 61.7% per year as a challenge for a cautious view, because it shows that the business has not yet translated its revenue base of roughly US$1.17b a year into consistent positive net income.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Ingevity on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of risks and potential rewards feels finely balanced, it may be worth acting promptly and reviewing the numbers yourself, including 2 key rewards and 1 important warning sign.

See What Else Is Out There

Ingevity is still dealing with trailing losses, a high debt load and a mixed earnings record, which together leave little room for error.

If that combination of losses and leverage feels uncomfortable, you might want to check out 80 resilient stocks with low risk scores today and compare businesses built around more resilient financial profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com